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Upregulation of the Expression of Infl ammatory and Angiogenic Markers in Human Adipocytes by a Synthetic Cannabinoid, JTE-907
cloning of the cannabinoid receptors CB 1 and CB 2 (nomenclature follows Alexander, Mathie, and Peters [1] ), and subsequently the discovery of the fi rst endocannabinoids, anandamide and 2-arachidonoylglycerol (2-AG) [2 -4] . More recently, other putative ECS receptors, such as TRPV1 (transient receptor potential cation channel, subfamily V, member 1) and GPR55 (G protein-coupled receptor 55) , have been recognized [5, 6] . The tissues and organs where the various ECS receptors are expressed is still unclear, but in humans the CB 1 receptor is mainly expressed in the brain with some expression in a range of other tissues, including kidney, liver, lung, skeletal muscle, and adipose tissue [7 -9] . The TRPV1 receptor is highly expressed in human sensory neurons [10] , but it is also expressed in human adipose tissue [11] . On the other hand, the CB 2 receptor is expressed in macrophages [12] and expression is also reported in the rat central nervous system [13] , while there is some controversy about its presence in human adipose tissue depots [9, 11] . 
Introduction ▼
The medical properties of marijuana ( Cannabis sativa ) led to the discovery of the endocannabinoid system (ECS) in the early 1990s, with the Infl ammation in adipose tissue is a characteristic of obesity and the metabolic syndrome. It is suggested that the endocannabinoid system is involved in the regulation of infl ammatory and angiogenic processes within the tissue. Human subcutaneous preadipocytes (Zen Bio) were used as the source of human preadipocytes or adipocytes. Gene expression was examined by RT-PCR and real-time PCR. The secretion of infl ammation-related proteins was determined by an ELISA array. In experiments on adipocytes treated at day 14 post-diff erentiation, JTE-907, a synthetic cannabinoid, upregulated the expression of key infl ammatory markers -IL-6, MCP-1 and IL-1 β -and angiogenic factors -VEGF and ANGPTL4 -at 10 μ M after 20 h of treatment, having also increased the expression of TRPV1 at 10 μ M. JTE-907 showed no eff ect after 4 h. The ELISA array showed a 2.6-fold increase in IL-6 protein release. The eff ect of JTE-907 was inhibited by AM251 (CB 1 antagonist), and partially by arachidonyl serotonin (TRPV1 and FAAH antagonist). The CB 2 antagonist, AM630, partially upregulated the eff ect of JTE-907. Preadipocytes fed 14 days after 100 % confl uence exhibited downregulation of CB 1 , MCP-1, and IL-1 β , 20 h after having been exposed to JTE-907. CB 1 and TRPV1 receptors participate in the regulation of several infl ammatory and angiogenic factors in human adipocytes, indicating their potential value as targets for the treatment of disorders related to obesity.
The list of ligands of the cannabinoid receptors is extensive and is divided into 3 categories: phytocannabinoids (from plants), endocannabinoids (endogenous cannabinoids), and synthetic cannabinoids (developed as putative drugs). JTE-907, which is in this last category, binds to CB 1 and CB 2 cannabinoid receptors with a higher affi nity for the latter [14] . This synthetic compound appears to be an anti-infl ammatory or antiallergic agent [15 -17] . The ECS and its receptors CB 1 , TRPV1, and CB 2 have been linked to a wide range of functions, including: vascular and endocrine responses, neuroprotection and nociception, immune modulation, stress recovery, food intake, energy balance, and metabolic homeostasis [18 -20] . Of particular interest is the role of the ECS in appetite and the regulation of energy balance [21] , CB 1 receptor blockade in animals and humans producing a reduction in body weight and an improvement of the comorbidities of obesity [22, 23] . Obesity is a major public health problem in most developed countries and in the UK, for example, 25 % of adults are now clinically obese with a BMI ≥ 30. Obesity is characterized by chronic low grade infl ammation [24 -26] and this has been linked to the development of the associated comorbidities, particularly the components of the metabolic syndrome [27, 28] . Adipose tissue is a major site of infl ammation in obesity, with the adipocytes secreting a number of cytokines, chemokines, and other infl ammation-related factors, including those involved in angiogenesis [26, 29] . Several studies have demonstrated the importance of the ECS in infl ammatory processes and angiogenic events; for example, in human macrophages [30] , mouse obese models [20] , mouse cutaneous tissue [17] , rat mesenteric arteries, and human cerebral artery endothelial cells [17, 30, 31] . Little is known, however, of the genes whose expression may be modulated through the endocannabinoid system. The aim of the present study was to examine the eff ects of the ECS on the expression of key infl ammatory and angiogenic genes in human white adipocytes. The results suggest that CB 1 and TRPV1 receptors participate in the regulation of several important infl ammatory and angiogenic factors in human adipocytes and preadipocytes. These key cannabinoid receptors could be a target for the pharmacotherapy of infl ammatory and angiogenic events within adipose tissue.
Materials and Methods

▼ Cell culture
Human subcutaneous preadipocytes and culture media were obtained from Zen-Bio (Durham, NC, USA) and cultured as previously [32] . Cells were from 5 female patients of average age 45.6 years and with a mean BMI of 27.9. The cells were plated at a density of 40 000 / cm 2 onto a 24-well plate and maintained in preadipocyte medium (PM) containing DMEM / Ham ' s F-12 (1:1, v / v), 10 % fetal calf serum (FCS), 15 mM HEPES, 100 U / ml penicillin, 100 μ g / ml streptomycin, and 0.25 μ g / ml amphotericin B at 37 ° C in a humidifi ed atmosphere of 95 % air / 5 % CO 2 . The cells were induced at confl uence by incubation in diff erentiation medium composed of adipose medium (AM) supplemented with 0.25 mM isobutylmethylxanthine and 10 μ M of a PPAR γ agonist for 5 days. The cells were then cultured with AM containing DMEM / Ham ' s F-12 (1:1, v / v), 3 % FCS, 100 nM insulin, 1 μ M dexamethasone, 100 U / ml penicillin, 100 μ g / ml streptomycin, and 0.25 μ g / ml amphotericin B [33] . The medium was changed every 3 days.
Preadipocytes (fed 14 days after 100 % confl uence) were exposed to JTE-907 (10 μ M) for 20 h. Fully diff erentiated cells at day 14 post-induction were exposed to JTE-907 (1 μ M or 10 μ M) for 4 or 20 h, and to AM251 (100 nM), A. S. (arachidonyl serotonin, 10 μ M) and AM630 (10 μ M) (all reagents were from Tocris Bioscience, Bristol, UK). The cells were harvested in 500 ml TRI ® Reagent (Sigma-Aldrich, St. Louis, MO, USA). Culture media were also collected. All incubations at each time point were performed in replicates of up to 6 wells.
RNA extraction and RT-PCR
Total RNA was isolated from cells using TRI ® reagent and treated with Turbo DNA-free ™ (Applied Biosystems / Ambion, Austin, TX, USA) according to the manufacturer ' s instructions. 1 μ g of DNaseI-treated RNA was reverse transcribed to obtain cDNA with Reverse-iT 1st Strand Synthesis kit (Abgene, Epsom, UK) in the presence of anchored oligo dT in a total volume of 20 μ l. Primers were designed using Primer Premier 5 software (Biosoft International, Palo Alto, CA, USA) and synthesized by MWG Biotech (Ebersberg, Germany). Primer sequence, size of the amplifi ed fragments, and optimal conditions of amplifi cation were as follows. PCR conditions were as follows: 2 min at 94 ° C for denaturation, followed by optimal cycles of 20 s at 94 ° C for denaturation, 30 s at the optimal annealing temperature, and 40 s at 72 ° C for extension, with a fi nal elongation step of 10 min at 72 ° C. Negative controls without templates were performed to exclude the formation of primer dimers. All primer pairs produced a single specifi c band. PCR products were analyzed by electrophoresis on a 1 % agarose gel with ethidium bromide staining and photographed under UV transillumination. The products were sequenced by MWG Biotech (Ebersberg, Germany) to confi rm their identity.
Real-time PCR
Quantitative real-time PCR was carried out in a fi nal volume of 12.5 μ l consisting of 12.5 -100 ng reverse-transcribed cDNA mixed with optimal concentrations of primers and probe and qPCR Core kit (Eurogentec, Southampton, UK) in 96-well plates on a Stratagene M × 3005P detector. The primer and probe sets were designed using Primer Express software (Applied Biosystems) and synthesized commercially (Eurogentec). The sequence and optimal concentrations of primers and probes together with the size of products were as detailed previously for β -actin, IL-6 (interleukin 6), MCP-1 (monocyte chemotactic protein-1), TNF α (tumor necrosis factor-alpha), and ANGPTL4 (FIAF, angiopoietin-like protein 4) [33, 34] . CB 1 , TRPV1, VEGF (vascular endothelial growth factor) and IL-1 β were as follows.
Typically, the amplifi cation started with 2 min at 50 ° C, 10 min at 95 ° C, and then 40 cycles of the following: 15 s at 95 ° C and 1 min at 60 ° C. Human β -actin was used as an endogenous reference; its expression remained unchanged both in response to the various treatments and during preadipocyte diff erentiation. Relative quantitation values were expressed using the 2 − Δ Δ Ct method (see User Bulletin 2, ABI PRISM 7700, pp 11 -15, Applied Biosystems) as fold changes in the target gene normalized to the reference gene ( β -actin) and related to the expression of the untreated controls. The PCR effi ciency in all runs was close to 100 % , and all samples were analyzed in at least duplicate.
Measurement of adipokines by ELISA
IL-6, MCP-1, TNF α , and IL-1 β were measured in cell culture media among 8 other proteins using a commercial ELISA array for autoimmune disease (MEH-005A; SABiosciences Corporation, Frederick, USA). The assays were conducted in 96-well microplates, according to the manufacturer ' s instructions.
Statistical analysis
The statistical signifi cance of diff erences between groups was assessed by Student ' s t -test. A p-value of < 0.05 was considered to be statistically signifi cant.
Results
▼ Expression of cannabinoid receptor genes in diff erentiated adipocytes and preadipocytes
We fi rst investigated whether the human white adipocytes used here express the cannabinoid receptor genes when diff erentiated in culture. RT-PCR was performed on mRNA from mature adipocytes (14 days post-induction). The results showed that the mRNAs for the genes encoding CB 1 and TRPV1 were present in the diff erentiated adipocytes at day 14 ( • ▶ Fig. 1a by real time-PCR), but CB 2 was not expressed in these cells (data not shown). The pattern of expression was the same for preadipocytes. CB 1 and TRPV1 were also present in preadipocytes as shown in • ▶ Fig.   4a (vide infra) by real time-PCR; and CB 2 was not expressed in preadipocytes either (data not shown). The primers for CB 2 were previously tested with mRNA obtained from a human macrophage-like cell line (U937) as a positive control, attaining a clear signal, which was confi rmed by sequencing.
Upregulation of cannabinoid receptors, infl ammatory, and angiogenic genes by JTE-907
In pilot experiments, the eff ects of several CB 1 and CB 2 agonists and antagonists, at diff erent doses, on the expression of infl ammation-related genes in human adipocytes were examined and particularly strong responses were obtained with JTE-907 (results not shown). In subsequent experiments, human preadipocytes were diff erentiated and exposed to JTE-907 at day 14 post-induction at which time they contained multiple lipid droplets. The mRNA levels of several genes were measured 20 h after exposing the human adipocytes to JTE-907 at 2 diff erent doses (1 and 10 μ M) ( • ▶ Fig. 1 ). Firstly, 2 cannabinoid receptor genes (CB 1 and TRPV1) were analyzed ( • ▶ Fig. 1a ). At 1 μ M no eff ect was found on the mRNA levels of the 2 receptors. At the second dose (10 μ M), CB 1 mRNA level was not signifi cantly changed and TRPV1 mRNA level was increased 3-fold. Subsequently, the mRNA levels of infl ammatory markers (IL-6, MCP-1, TNF α , and IL-1 β ) and angiogenic factors (VEGF and ANGPTL4) were quantitated ( • ▶ Fig. 1b ) . The lowest dose (1 μ M) produced no eff ect on the mRNA level of any of the genes. The highest dose (10 μ M) increased IL-6, MCP-1, IL-1 β , VEGF, and ANGPTL4 mRNA levels by 41-, 7-, 6-, 6-, and 3-fold, respectively; however, this dose did not aff ect TNF α gene expression. Doses of 1 and 10 μ M of JTE-907 were used in vitro previously by another group [14] , without damage to the cells, and a dose of 50 μ M in our studies led to similar eff ects as 10 μ M. Exposure of diff erentiated human adipocytes (14 days) to JTE-907 at 10 μ M for 4 h did not result in any signifi cant change in the level of the mRNA for any of the genes mentioned previously ( • ▶ Fig. 2a, b ) . IL-6, MCP-1, TNF α , and IL-1 β proteins were measured, in addition to 8 other proteins involved in autoimmune disease, in the medium using a commercial ELISA array in the cells incubated with 10 μ M JTE-907 for 20 h. The ELISA array showed a 2.6-fold increase in IL-6 release ( • ▶ Fig. 2c ), which was statistically signifi cant, consistent with the mRNA measurements. The secretion levels of other relevant proteins, such as TNF α and IL-1 β , were below the detection sensitivity of the array. There was no signifi cant change in MCP-1 release.
Eff ect of cannabinoid receptor antagonists on the response to JTE-907
The upregulation of several genes by JTE-907 (10 μ M for 20 h) on diff erentiated human adipocytes (14 days) was inhibited when AM251 (100 nM), a CB 1 receptor antagonist, was added at the same time ( • ▶ Fig. 3a, b ) . TRPV1 mRNA level was reduced 4-fold, although no signifi cant eff ect was found on CB 1 gene expression ( • ▶ Fig. 3a ) . The mRNA levels of IL-6, MCP-1, IL-1 β , VEGF, and ANGPTL4 decreased 29-fold, 5-fold, 3-fold, 6-fold and 3-fold, respectively; this antagonist did not aff ect TNF α gene expression ( • ▶ Fig. 3b ).
Arachidonyl serotonin (A.S.), considered to be a TRPV1 and FAAH (degrading enzyme of anandamide) antagonist [35] , partially inhibited the eff ect of JTE-907 on diff erentiated (14 days) human adipocytes when the 2 agents were added together (both at 10 μ M for 20 h) ( • ▶ Fig. 3c, d ). TRPV1 mRNA expression was reduced 3-fold, although no signifi cant eff ect was found on CB 1 gene expression ( • ▶ Fig. 3c ). The expression of IL-6, MCP-1, VEGF, and ANGPTL4 was signifi cantly lower than with JTE-907 alone, being 10-fold, 6-fold, 5-fold, and 4-fold lower, respectively; TNF α and IL-1 β gene expression remained unaltered ( • ▶ Fig. 3d ).
Interestingly, AM630 (a CB 2 antagonist), partially upregulated the eff ect of JTE-907 alone ( • ▶ Fig. 3e, f ) . AM630 and JTE-907 (both 10 μ M) were added simultaneously to diff erentiated human adipocytes and the cells were collected 20 h later. CB 1 and TRPV1 mRNA levels were augmented 1.5-fold and 3-fold, respectively ( • ▶ Fig. 3e ), while MCP-1 and ANGPTL4 expression was increased 2-fold and 4-fold, respectively ( • ▶ Fig. 3f ). There was no eff ect of AM630 on IL-6, TNF α , IL-1 β , and VEGF gene expression ( • ▶ Fig. 3f ).
Diff erential eff ects of JTE-907 on the expression of preadipocytes genes
The eff ect of JTE-907 on the expression in preadipocytes of those genes sensitive to the compound in adipocytes was then examined. Human preadipocytes were fed 14 days after reaching 100 % confl uence and exposed to JTE-907 at 10 μ M for 20 h ( • ▶ Fig. 4 ) . Expression of the CB 1 receptor was slightly downregulated (56 % reduction) in preadipocytes with no signifi cant eff ect in mature adipocytes ( • ▶ Fig. 4a ). The mRNA level of 2 genes involved in infl ammation, MCP-1 and IL-1 β , was reduced by approximately 60 % in preadipocytes ( • ▶ Fig. 4b ), which was in contrast to increases of more than 700 % and 600 % , respectively, in mature adipocytes ( • ▶ Fig. 1b ).
Discussion and Conclusions ▼
The high and growing incidence of obesity and its associated disorders now represents a major public health problem [36] . The endocannabinoid system and its relation with metabolism, infl ammation, and angiogenesis have been considered as one of the key targets in the treatment of obesity and its comorbidities, among other diseases [7, 18, 37, 38] . Cannabinoid receptors are mainly expressed in the central nervous system, but their peripheral location and eff ects are becoming of increasing interest [30, 39] . The present study has examined the eff ects of JTE-907, a synthetic cannabinoid [14] , on the expression of 2 receptors of the ECS (CB 1 and TRPV1) and on the expression of major adipokine genes in preadipocytes and in mature adipocytes. White adipose tissue secretes a large number of protein signals and protein factors, termed adipokines. The production and circulating level of some of these adipokines is increased in obese patients, for example IL-6, MCP-1, and TNF α [25, 40] while their gene expression is reduced in adipose tissue after weight loss, as is the case with IL-1 β [41] . The expression of some adipokines, such as leptin, VEGF, ANGPTL4 [32] , and RANTES (an immune mediator) [42] , is increased under hypoxic conditions, and low oxygen tension has been proposed as a key trigger for the mild chronic infl ammatory state associated with obesity [26] . Furthermore, there is a link between these adipokines and the comorbidities associated with obesity [43, 44] . Within human white adipose tissue, CB 2 gene and protein expression in preadipocytes and mature adipocytes isolated from omental and subcutaneous tissue has been reported by some authors [9] , while others [11] were unable to detect CB 2 gene expression in adipocytes and tissue from the subcutaneous fat depot. Our results are consistent with the latter, confi rming the expression of CB 1 and TRPV1, but not of CB 2 in human adipocytes. The key fi ndings from the present study are that JTE-907 is able to regulate the expression of receptor genes, which are part of the ECS (CB 1 and TRPV1 receptors), together with a proinfl ammatory behavior and the upregulation of genes associated with angiogenesis (VEGF and ANGPTL4). Previous studies have shown that JTE-907 has an anti-infl ammatory action in mouse cutaneous tissue [14 -17] , but no eff ect of JTE-907 has been found in human colon [45] . In these investigations, JTE-907 was believed to be acting through the CB 2 receptor; however, in our study, due to the absence of expression of CB 2 receptors in human adipocytes the actions of this ligand are more likely to occur through CB 1 or TRPV1. Therefore, the cells were exposed to an antagonist of CB 1 (AM-251), CB 2 (AM-630) and TRPV1 and FAAH (arachidonoyl serotonin) in diff erent experiments, in order to determine the probable route of action of JTE-907 within human white adipocytes. Interestingly, the compound appeared to operate through CB 1 and TRPV1, either acting through both directly or through 1 receptor, which would subsequently activate the second; the last mechanism has been demonstrated by other authors [19, 46] . The importance of the TRPV1 receptor in obesity is unclear, with 2 important studies showing contrasting results [47, 48] . AM630, an antagonist or inverse agonist for CB 2 , which may act as an inverse agonist [49] or weak partial agonist of the CB 1 receptor [50] , augmented the eff ects obtained with JTE-907 alone in the case of genes such as CB 1 , TRPV1, MCP-1, and ANGPTL4. In a recent study, Hoareau et al. [51] reported anti-infl ammatory actions of SR141716 (also known as Rimonabant, a CB 1 antagonist) and SR144528 (a CB 2 antagonist) against LPS stimulation in mature adipocytes obtained from human subcutaneous adipose tissue, with stronger eff ects with the latter. These and other recent results confi rming the anti-infl ammatory actions of a CB 1 antagonist like Rimonabant [30, 52] , may support the idea that AM630 and JTE-907 are exerting their proinfl ammatory actions as agonists of CB 1 . In addition, there is evidence relating some CB 1 agonists with anti-infl ammatory actions, such as WIN55,212-2 [53, 54] , ACEA [55] or anandamide (CB 1 and CB 2 agonist) [56] , or with proinfl ammatory actions, like anandamide [57] . This confi rms the fact that diff erent or even the same, endocannabinoids may work in opposite ways. The increased secretion of IL-6 protein in response to JTE-907 underlines the proinfl ammatory property of this compound in human adipocytes and indicates that the changes in gene expression are refl ected by parallel alterations in the amount of the encoded protein.
The relationship between angiogenesis and JTE-907 has not been described previously. Furthermore, it is the fi rst time this synthetic cannabinoid has been found to upregulate the expression of genes associated with a proinfl ammatory state and to have a proangiogenic eff ect. The receptors, CB 1 and TRPV1, have been linked to infl ammation and cardiovascular responses [18, 19] . This would indicate that in adipocytes JTE-907 might be acting as an agonist for these receptors. There is increasing recognition of the importance of other cells, apart from mature adipocytes, in the function of white adipose tissue, including infl ammation. This is particularly evident with respect to macrophages which are recruited during the expansion of adipose mass in obesity, and this is considered to be a key component of the infl ammatory response. Preadipocytes are also increasingly recognized to be major players in adipose tissue infl ammation [58, 59] . However, JTE-907 did not aff ect in preadipocytes those same genes that were upregulated in the mature adipocytes. In practise, for those genes in preadipocytes that were infl uenced by the treatment, there was a downregulation in contrast to the upregulation in the mature adipocytes. Previous studies have shown that the preadipocytes may show a similar, or opposite, behavior to mature adipocytes, depending on the parameter [60, 61] . Infl ammation and angiogenesis are key processes in obesity, the metabolic syndrome, and a number of other diseases. The present study suggests that CB 1 and TRPV1 receptors participate in the regulation of the expression of several important infl ammatory and angiogenic gene factors in human mature adipocytes. Understanding the mechanism of action of the diff erent cannabinoid receptors within adipose tissue and other peripheral sites may be valuable in the development of pharmacological treatments for obesity-associated diseases. Human preadipocytes fed 14 days after 100 % confl uence were exposed for 20 h to JTE-907 (10 μ M). a : CB 1 and TRPV1 gene expression. b : Expression of infl ammatory marker genes and angiogenic factors. mRNA levels were normalized to human β -actin. Means ± SE; n = 6. * * p < 0.01 compared with control.
